Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (31)

I-22Linda Aulin

Physiologically-based pharmacokinetic model to predict lung distribution of anti-infective agents

Wednesday 09:50-11:15

I-27Vanessa Baier

Assessing the cholestatic potential of drugs using a physiology-based model of the bile acid metabolism

Wednesday 09:50-11:15

I-28Pavel Balazki

A mechanistic model of gastric emptying of caloric liquids and solids for the use in physiologically-based pharmacokinetics models.

Wednesday 09:50-11:15

I-82Mailys De Sousa Mendes

Transporter inhibition: modelling in-vitro Transwell assays

Wednesday 09:50-11:15

II-06Jennifer Lang

Combining physiologically-based-pharmacokinetic modelling and a Bayesian method for prediction of ivabradine oral absorption and drug-drug interactions

Wednesday 15:10-16:40

II-15Anja Lehmann

Toxicokinetic modelling of hepatotoxic pyrrolizidine alkaloids: a combined in silico, in vitro and in vivo approach

Wednesday 15:10-16:40

II-28Ulrich Ruben Luecht

Physiologically based pharmacokinetic modeling approach to assess drug-drug interactions (DDI) between psychopharmaceuticals – focus on mirtazapine and venlafaxine

Wednesday 15:10-16:40

II-33Panos Macheras

On the unphysical hypotheses in pharmacokinetics and oral drug absorption:Time to utilize instantaneous rate coefficients instead of rate constants

Wednesday 15:10-16:40

II-39Fatima Zahra Marok

Physiologically-based pharmacokinetic modeling of DPYD substrate 5-fluorouracil and its prodrug capecitabine

Wednesday 15:10-16:40

II-40Frederico Martins

Application of Physiologically Based Pharmacokinetic (PBPK) Modelling to Support First in Human dose selection.

Wednesday 15:10-16:40

II-44Nicola Melillo

Global sensitivity analysis of a physiologically based pulmonary absorption model

Wednesday 15:10-16:40

II-51

Biotest’s Pentaglobin® in adults and neonates (term and preterm) – A PBPK approach

Wednesday 15:10-16:40

II-82Luna Prieto Garcia

Physiologically-based pharmacokinetic model for itraconazole and its metabolites: the importance of parameter sensitivity analysis

Wednesday 15:10-16:40

II-84Rajith Rajoli

PBPK Modelling of Atovaquone Long-acting Injectable Formulations

Wednesday 15:10-16:40

III-13Annika Schneider

A PBPK approach for simulating the effect of liver cirrhosis on drug PK

Thursday 09:55-11:20

III-16Dmitry Shchelokov

Physiologically based pharmacokinetic modeling of anti-PD-1 therapeutic antibodies

Thursday 09:55-11:20

III-17Soyoung Shin

Novel population approach to establish in vitro-in vivo correlation for drugs with site-dependent absorption

Thursday 09:55-11:20

III-20Florian Simon

A generic PBPK model for predicting the impact of inflammation on midazolam pharmacokinetics

Thursday 09:55-11:20

III-47Denise Feick

Physiologically-based pharmacokinetic modeling of the CYP2C8 perpetrator trimethoprim

Thursday 09:55-11:20

III-62Ludwig Vincent

How to improve the accuracy of Drug-Drug Interaction risk prediction for Mechanism Based Inhibitors

Thursday 09:55-11:20

III-69Shayne Watson

Development and Evaluation of a Human Physiologically Based Pharmacokinetic Model to Assess a Mitigation Strategy for Risks Associated with Novel Monoclonal Antibodies

Thursday 09:55-11:20

III-78Jan-Georg Wojtyniak

Physiologically-based Pharmaokinetic Modelling of Metoprolol Drug-Drug-Gene Interactions with Paroxetine and CYP2D6

Thursday 09:55-11:20

III-82Estelle Yau

A global sensitivity analysis of the Rodgers and Rowland equations predicting drug distribution in PBPK models

Thursday 09:55-11:20

IV-08Esther Encinas

Use of modeling and simulation methods to support the generic application of a vaginal delivery system

Thursday 15:25-16:50

IV-15Rebekka Fendt

Evaluating the benefit of individual patient data for physiologically based pharmacokinetic (PBPK) simulations

Thursday 15:25-16:50

IV-21Laura Fuhr

Physiologically based pharmacokinetic modeling of the dabigatran antidote idarucizumab

Thursday 15:25-16:50

IV-24Fiona G. Gao

Prediction of human pharmacokinetics of subcutaneously administered insulin formulations

Thursday 15:25-16:50

IV-36Silvia Grandoni

Development and evaluation of a PBPK model to study the pharmacokinetics of inhaled drugs in rats

Thursday 15:25-16:50

IV-49Lukas Kovar

Physiologically-based pharmacokinetic (PBPK) modelling of nicotine and its main metabolite cotinine in healthy volunteers and smokers

Thursday 15:25-16:50

IV-50Anneke Himstedt

Prediction of pulmonary exposure based on plasma pharmacokinetics: A comparison of different model-based approaches.

Thursday 15:25-16:50

IV-87Lisa Alina Kneller

Impact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on Risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach

Thursday 15:25-16:50